Could RO7851624, newly into clinical trials, be RG6735?
ApexOnco Front Page
Recent articles
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
A US advisory committee votes against camizestrant, but does endorse a new use for Truqap.
MK-6837 has been discontinued, the company discloses.
The company discontinues the Lag3 project in lung cancer.
Dispatch Bio’s virus therapy DV-10 enters phase 1.
The QCS assay for TROP2 is being implemented more broadly, at the cost of further readout delays.
ERAS-0015 data look good, but the company is punished for a pneumonitis death.
